Juun 19, Xarunta Qiimaynta Daawada (CDE) ee Maamulka Badeecadaha Caafimaadka Qaranka (NMPA) ayaa ku dhawaaqday in IBI343 ee Innovent Biologics loo soo jeediyay in lagu daro barnaamijka magacaabista daaweynta degdegga ah, oo loogu talagalay daaweynta kansarka ganaca ee maxalliga ah ama kansarka faafa ee CLDN18.2-positive ah isla markaana helay ugu yaraan laba daaweyn oo nidaamsan oo hore.
IBI343 waa isku-darka daawada antibody-ga ee dib-u-habaynta ah (ADC). Marka ay ku xidhnaato unugyada burooyinka ee muujiya CLDN18.2, waxay martaa gudaha ADC ee ku tiirsan CLDN18.2 waxayna sii daysaa culays sun ah, taasoo keenta dhaawac DNA ah ugu dambayntiina keenta apoptosis unugyada burooyinka.
Diseembar 9, 2024, xogtii ugu dambeysay ee laga helay tijaabada kiliinikada ee Wejiga I (NCT05458219) ee IBI343 ee adenocarcinoma-ka qanjirka 'pancreatic ductal adenocarcinoma' (PDAC) ayaa lagu soo bandhigay Shirka Sanadlaha ah ee Bulshada Yurub ee Cudurrada Caafimaadka Aasiya (ESMO Asia).
Wadarta guud ee 43 bukaan oo qaba CLDN18.2-positive PDAC ayaa lagu daweeyay IBI343. Natiijooyinku waxay muujiyeen heer jawaab celin guud oo ujeedo leh (ORR) oo ah 32.6%, heer jawaab celin ujeedo leh oo la xaqiijiyay (cORR) oo ah 23.3%, iyo heer xakameyn cudur oo la xaqiijiyay (cDCR) oo ah 81.4%. Muddada dhexdhexaadka ah ee jawaab celinta (mDoR) waxay ahayd 7.0 bilood, iyadoo heerka DoR ee 6-bilood ah uu ahaa 63%, iyo badbaadada dhexdhexaadka ah ee aan horumarka lahayn (PFS) oo ahayd 5.3 bilood.
Waqtigan xaadirka ah, waxaa weli jira tijaabooyin caafimaad oo badan oo ku saabsan teknoolojiyada cusub ee ka hortagga kansarka ee Shiinaha oo raadinaya bukaanno. La-tashi ku saabsan daawooyinka cusub iyo teknoolojiyada, waxaad la xiriiri kartaa Waaxda Caalamiga ah ee Isbitaalka Oncology ee Gobolka Koonfureed ee Beijing.
Lambarka Taleefanka: 4008803716
Email：myimmnet@163.com
Waqtiga boostada: Juun-19-2025